Atreca Inc. Stock News

Atreca (NASDAQ: BCEL ) stock is rising higher on Thursday following news of a major stake in the clinical-stage biopharmaceutical company from an investment advisor. According to a filing with the Se

Atreca (BCEL) suspends the development of only pipeline candidate, ATRC-101, in clinical evaluation, as part of its business restructuring efforts and cuts headcount by 40%. The stock falls 37%.

Tech companies in certain high-growth sectors like semiconductors, AI, and cloud predominantly drove this year's bull market. But while these giants made headlines, many penny stocks continued trading

Atreca, Inc. (NASDAQ:BCEL ) Q4 2022 Earnings Conference Call March 29, 2023 4:30 PM ET Company Participants Alex Gray - Head of Investor Relations John Orwin - CEO Tito Serafini - Chief Strategy Offic

Call/webcast to feature updates on the discovery platform and pipeline, including updated data from the ongoing Phase 1b trial of ATRC-101 Call/webcast to feature updates on the discovery platform and

Atreca (NASDAQ: BCEL ) stock is getting a boost on Tuesday as the company continues a recent rally connected to insider buying. On Monday, shares of BCEL stock jumped nearly 14% after a series of fili

BCEL is set to produce additional data from a phase 1b trial of its antibody ATRC-101 in multiple solid tumor types. Based on previous data, BCEL has refined the patients it enrolls in the trial, whic

SAN CARLOS, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique d

SAN CARLOS, Calif., Sept. 09, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique

SAN CARLOS, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique d

SAN CARLOS, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique di

Preliminary evidence shows that ATRC-101 helps those patients with higher target expression; 8 out of 12 patients (66%) who took ATCR-101 with H-score ≥ 50 responded. Phase 1b study was updated to

SAN CARLOS, Calif., April 08, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a uniqu

SAN CARLOS, Calif., April 08, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique

Atreca Inc (NASDAQ: BCEL) announced a licensing agreement with Zymeworks Inc (NYSE: ZYME) to utilize their ZymeLink technology to develop novel antibody-drug conjugates (ADCs). The agreement incl